BLVIS A Blue Vision A

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026

3 December 2025

Company Announcement no. 14



Pharma Equity Group A/S (“PEG”) announces that the Company’s agreement with Danske Bank as liquidity provider will terminate with effect from 1 January 2026.

In connection with the termination of the agreement, the Company has evaluated its current market strategy. It is the management's assessment that, at this stage, greater value is created for shareholders by allocating resources to direct and targeted communication and Investor Relations activities rather than a contracted market maker arrangement.

Consequently, PEG has chosen not to enter into an agreement with a new liquidity provider upon the expiration of the current agreement.

The last trading day with Danske Bank acting as liquidity provider is 31 December 2025.

The Company notes that this change may technically affect the liquidity of PEG’s share, including the bid-ask spread, as there will no longer be an external party obligated to provide bid and ask quotes from the turn of the year.

This decision does not alter PEG’s overall strategic direction regarding business development.

Further information:

Christian Vinding Thomsen, Chairman of the Board, Tel.

Christian Tange, CEO, Tel.

About Pharma Equity Group A/S

Pharma Equity Group (PEG) is a dynamic investment and development company within Life Science and is listed on Nasdaq Copenhagen. PEG identifies, acquires and develops innovation projects within pharmaceuticals, MedTech and other medical devices with a particular focus on early-stage innovation projects, especially those originating from

Scandinavian research institutions. Through strategic capital allocation, strong governance with a dedicated investment committee, and an extensive industry network, PEG works to convert groundbreaking ideas into impactful healthcare solutions and products. The Company aims to build a balanced portfolio that creates continuous value and supports long-term growth—for the benefit of patients, healthcare systems and investors.

Attachment



EN
03/12/2025

Underlying

BLVIS ABlue Vision A

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Blue Vision A

 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group eksekverer på selskabets nye strategi: Indgår hens...

Pharma Equity Group eksekverer på selskabets nye strategi: Indgår hensigtserklæring om opkøb af MedTech-virksomheden Otiom A/S Pharma Equity Group eksekverer på selskabets nye strategi: Indgår hensigtserklæring om opkøb af MedTech-virksomheden Otiom A/S København, 10. december 2025 Selskabsmeddelelse nr. 15 Pharma Equity Group A/S ("PEG") meddeler i dag, at selskabet har underskrevet en hensigtserklæring (Letter of Intent) om erhvervelse af hele aktiekapitalen eller en majoritetsandel i Otiom A/S. Transaktionen markerer første konkrete skridt i PEG’s udvidede strategi om at blive en mark...

December 10, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group executes on the Company's new strategy: Enters in...

Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S Pharma Equity Group executes on the Company's new strategy: Enters into Letter of Intent to acquire the MedTech company Otiom A/S Copenhagen, 10 December 2025 Company Announcement no. 15 Pharma Equity Group A/S ("PEG") today announces that the company has signed a Letter of Intent regarding the acquisition of the entire share capital or a majority stake in Otiom A/S. The transaction marks the first concrete step in PEG’s expanded strategy to become a leading ...

December 10, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group A/S aftale med Danske Bank som liquidity provider ...

Pharma Equity Group A/S aftale med Danske Bank som liquidity provider ophører 1. januar 2026 Pharma Equity Group A/S aftale med Danske Bank som liquidity provider ophører 1. januar 2026 3. december 2025 Selskabsmeddelelse nr. 14 Pharma Equity Group A/S (”PEG”) meddeler, at selskabets aftale med Danske Bank som liquidity provider ophører pr. 1. januar 2026. I forlængelse af aftalens ophør har selskabet vurderet sin nuværende markedsstrategi. Det er ledelsens vurdering, at selskabet på nuværende tidspunkt skaber større værdi for aktionærerne ved at allokere ressourcerne til direkte og m...

December 3, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provi...

Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026 Pharma Equity Group A/S’ agreement with Danske Bank as liquidity provider will terminate on 1 January 2026 3 December 2025 Company Announcement no. 14 Pharma Equity Group A/S (“PEG”) announces that the Company’s agreement with Danske Bank as liquidity provider will terminate with effect from 1 January 2026. In connection with the termination of the agreement, the Company has evaluated its current market strategy. It is the management's assessment that, at this stage, greater valu...

December 3, 2025 1 EN
 PRESS RELEASE
Free
BLVIS A BLUE VISION A

Bestyrelsens beslutning om udstedelse af konvertible lån

Bestyrelsens beslutning om udstedelse af konvertible lån Bestyrelsens beslutning om udstedelse af konvertible lån 1. december 2025Meddelelse nr. 13 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af konvertible obligationer i henhold til bemyndigelsen i selskabets vedtægter under pkt. 4.3.A. Der udstedes konvertible obligationer for nominelt DKK 8.798.336. I forbindelse hermed indfris tidligere udstedte konvertible obligationer for nominelt DKK 600.000 udstedt 1. april 2025, tidligere udstedte konvertible obligationer for nominelt DKK 1.000.000 udstedt 6. februar 20...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch